Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
ROSELAND, N.J., March 21, 2017 -- Emisphere (OTCQB:EMIS) announced today that management will host a conference call to discuss the Company's financial and operational results for the twelve months ended December 31, 2016, on Wednesday, March 29, 2017, at 8:30 AM ET. A press release will be issued prior to market open.
The live webcast of the conference call can be accessed through the Company's web site at www.emisphere.com. The call can also be accessed by dialing (877) 303-9483 (United States and Canada) or (760) 666-3584 (international), and entering Conference ID# 90730730.
In addition, an archive of the webcast can be accessed through the same link and an audio replay of the call will be available beginning Wednesday, March 29, 2017 at 11:30 AM ET through 11:30 AM ET on April 05, 2017, by calling (855) 859-2056 (United States and Canada) or (404) 537-3406 (International), and entering Conference ID# 90730730.
About Emisphere
Emisphere Technologies is a Drug Delivery Company whose core business strategy is to partner its proprietary drug delivery technology and license Eligen B12. Our thirty year history has made us the established leader in converting injectable therapeutics into advanced oral therapeutics. Utilizing our experience in researching, developing and manufacturing a number of fully characterized carriers in our extensive library, our partners leverage our expertise to employ our unique intracellular delivery mechanism to advance their portfolio and create differentiated line extensions. Our capabilities range from early proof of concept, to extensive development and commercial capabilities.
Emisphere’s technology can enhance the clinical profile of both pre-market and currently marketed products. Further, our broad-based proprietary oral drug delivery platform provides significant increases in bioavailability, facilitates the enhanced absorption of small and large molecules without altering their chemical form, and maintains their biological integrity or pharmacological properties. Finally, it is especially useful for oral delivery of peptides, proteins, oligonucleotides and oligosaccharides. For more information please visit www.emisphere.com.
CONTACT: Alan L. Rubino, CEO 973.532.8000 [email protected]
